→ The Bill & Melinda Gates Foundation has come in with a major assist at Achaogen $AKAO. The nonprofit will invest $10 million in the company and add a $10.5 million grant to fuel the biotech’s work on antibody candidates against gram-negative bacteria, including those that cause neonatal sepsis. That effort could help reduce neonatal mortality in developing countries.
→ Canada’s Theratechnologies reports that its partner, TaiMed Biologics, has completed the submission of a BLA to the FDA for its HIV drug ibalizumab. The company adds: “If approved, ibalizumab will be the first antiretroviral treatment (ART) with a new mechanism of action to be introduced in nearly 10 years and the only treatment that does not require daily dosing. As ibalizumab has received the Breakthrough Therapy and Orphan Drug Designations, TaiMed has requested Priority Review for the application.”
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 19,000+ biopharma pros who read Endpoints News by email every day.Free Subscription